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Abstract  Chronic  Obstructive  Pulmonary  Disease  (COPD)  is  currently  the  4th  leading  cause  of
death worldwide  but  is  projected  to  be  the  3rd  leading  cause  of  death  by  2020.  In  Portugal,
the estimated  prevalence  of  COPD  in  the  Lisbon  region  is  14.2%,  and  a  large  proportion  of
underdiagnosed  disease  has  been  detected.
In 2016,  a  Portuguese  panel  of  experts  proposed  pharmacological  treatment  approaches  to
COPD based  on  the  evidence  available  at  the  time.  However,  given  that  the  GOLD  2017  report
introduced  considerable  changes  to  the  2016  version,  and  that  new  evidence  has  emerged
regarding  treatment  options,  these  proposals  need  to  be  updated.  Also,  and  based  on  several
studies, the  concept  of  Pre-GOLD  patients,  which  has  diagnostic,  prognostic  and  therapeutic
implications,  is  introduced,  along  with  a  proposed  algorithm  for  the  identification  and  treatment
of these  patients.
© 2019  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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hronic  Obstructive  Pulmonary  Disease  (COPD)  is  currently
he  4th  leading  cause  of  death  worldwide  but  is  projected  to
e  the  3rd  leading  cause  of  death  by  2020.1 In  Portugal,  the
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and  a  large  proportion  of  underdiagnosed  disease  has  been
detected.2
In  2016,  a  Portuguese  panel  of  experts  proposed  phar-
macological  treatment  approaches  to  COPD  based  on  the
evidence  available  at  the  time.3 However,  the  GOLD  2017
report 4 introduced  considerable  changes  to  the  2016
version.5 According  to  the  2017  strategy,  COPD  patients
continue  to  be  separated  into  A,  B,  C  or  D  according
to  symptoms  and  exacerbations.  However,  previous  GOLD
reports  stratified  patients  considering  three  risk  variables
--  forced  expiratory  volume  in  1  second  (FEV1),  symptoms
and  exacerbations.5 The  implications  of  these  changes  are
that  patients  who  were  previously  considered  at  risk  due  to
poor  lung  function  only  (C  or  D),  will  now  be  classified  as
A  or  B,  respectively,  with  repercussions  in  the  therapeutic
strategy  recommended.  The  most  recent  GOLD  20181 did  not
introduce  changes  to  the  GOLD  2017  classification.4
Also,  the  FLAME  study6--8 provided  new  evidence  regard-
ing  treatment  options  for  B  and  D  patients,  showing
that  indacaterol/glycopyrronium  was  more  effective  than
salmeterol/fluticasone  in  reducing  and  preventing  COPD
exacerbations  in  patients  with  a  history  of  exacerbations
during  the  previous  year,  and  that  this  efficacy  was  inde-
pendent  of  different  cutoffs  of  baseline  blood  eosinophilia.
Finally,  and  based  on  several  studies,9--13 the  concept
of  Pre-GOLD  patients,  which  has  diagnostic,  prognostic  and
therapeutic  implications,  is  introduced,  along  with  a  pro-
posed  algorithm  for  the  identification  and  treatment  of
these  patients.
Pre-GOLD  patients
The  diagnosis  of  COPD  requires  a  ratio  of  FEV1 to  forced  vital
capacity  (FVC)  of  less  than  0.70  as  assessed  by  spirometry
after  bronchodilator  use.4 However,  a  recent  study  reported
that  50%  of  smokers  with  preserved  pulmonary  function
have  respiratory  symptoms,  including  exacerbations,
limitation  of  activity,  and  greater  airway-wall  thickening
without  emphysema.  Among  symptomatic  current  or  former
smokers,  42%  used  bronchodilators  and  23%  used  inhaled
glucocorticoids,  without  any  evidence  base.9 This  study  con-
firmed  previous  findings  reporting  that  the  effect  of  chronic
smoking  on  the  lungs  is  substantially  underestimated  if  just
spirometry  is  used.10 In  fact,  post-salbutamol  FEV1 change
is  similar  in  patients  with  COPD  and  smoking  controls11;
a  significant  proportion  of  smokers  with  emphysema  but
without  airway  limitation  had  alterations  in  their  quality  of
life,  number  of  exacerbations  and  diffusing  capacity  of  the
lungs  for  carbon  monoxide  (DLCO)  values.12 Taken  together,
all  these  studies  confirm  that  FEV1 is  an  unreliable  measure
of  symptom  burden  and  exacerbations  in  smokers,  but  leave
a  gap  on  how  to  treat  these  patients  in  order  to  reduce
symptoms  and  prevent  exacerbations.13 We  propose  a  diag-
nostic  and  treatment  algorithm  to  evaluate  and  medicate
these  patients  --  Fig.  1.  Every  smoker  or  former  smoker  with
symptoms  and  exacerbations  should  undergo  spirometry.  If
spirometry,  post-bronchodilator  FEV1/FVC  <  0.70,  values  are
consistent  with  the  GOLD  2018  criteria  for  COPD,  the  patient
should  be  treated  accordingly.  If  the  value  of  FEV1/FVC  is
between  0.6  and  0.8,  spirometry  should  be  repeated  on  a
separate  occasion,1 since  this  ratio  may  change  as  a  result
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f  biological  variation.14,15 If  the  initial  FEV1/FVC  ratio  is
ess  than  0.6  it  is  very  unlikely  that  it  will  rise  above  0.7
pontaneously.15 If  spirometry  values  are  not  in  accordance
ith  the  GOLD  2018  criteria  for  COPD,  and  symptoms  and
xacerbations  continue  to  persist,  the  patient  should  be
hecked  for  occult  airflow  obstruction  using  the  Lower  Limit
f  Normal  (LLN)  range.16 If  the  LLN  is  achieved,  the  patient
hould  be  diagnosed  with  COPD  and  treated  according
o  GOLD  2018.1 If  not,  and  symptoms  and  exacerbations
ontinue  to  persist,  a  complete  assessment  should  be  done,
ncluding  a  thoracic  Computerized  Tomography  (CT)  scan
or  the  differential  diagnosis  of  emphysema,  cancer  and
ther  lung  pathologies.  Regardless  of  whether  the  CT  scan  is
ositive  or  negative  for  emphysema/airway-wall  thickening,
he  patient  should  undergo  a  trial  with  a bronchodilator
nd  be  re-assessed  3--6  months  later.
This  concept  of  pre-GOLD  patients  we  here  introduce  is
ery  similar  to  that  recently  proposed  by  Celli  and  Agusti.17
n  their  work,  the  authors  argue  that  individuals  who  have
ymptoms  similar  to  those  of  patients  with  COPD  (namely,
yspnea,  cough  and/or  sputum  production)  and  structural
ung  abnormalities  but  without  persistent  airflow  limita-
ion  may  be  classified  as  ‘‘Pre-COPDs’’.  The  ‘‘Pre-COPDs’’
dea  has  wider  implications  than  our  pre-GOLD  concept,  as,
ccording  to  those  authors,  no  past  or  current  exposure  to
igarette  smoke  is  required.
OLD  A  patients
OLD  2017/2018  clearly  state  that  the  goals  of  treatment  for
table  COPD  are  to  reduce  symptoms  and  risk,  by  improv-
ng  exercise  tolerance  and  health  status  and  preventing
isease  progression,  exacerbations  and  mortality.1,4 Results
rom  a  large  recent  study  show  that  exacerbations  acceler-
te  lung  function  loss  in  subjects  with  established  COPD,
articularly  when  they  are  severe  and  occur  in  patients
ith  mild  disease.18 This  is  not  surprising  since  patients
ith  mild  disease  have  better  lung  function  and  therefore
ore  to  lose.  Also,  two  recent  expert  reviews  suggest  that
ore  aggressive  treatments  should  be  implemented  in  the
arlier  stages  of  COPD,19 in  order  to  slow  disease  progres-
ion  and  improve  Quality  of  Life  (QoL),20 thus  obtaining  the
est  possible  outcome.19 Current  data  support  maintenance
reatment  with  a  long-acting  bronchodilator  in  this  patient
roup.20 Given  the  above,  the  rationale  for  chronic  ther-
py  of  GOLD  A  patients  is  to  prevent  exacerbations  and
low  disease  progression.  The  GOLD  2016  report  proposed
hort  acting  beta  agonists  (SABA)  or  short  acting  muscarinic
ntagonists  (SAMA)  as  first  choice  therapy  in  these  patients,
ith  long  acting  beta  agonists  (LABA)  or  long  acting  mus-
arinic  antagonists  (LAMA)  or  SABA/SAMA  as  the  alternative
hoice.5 Before  the  GOLD  2017  report  was  published,  one
xpert  opinion  paper  proposed  a  SABA  or  SAMA  when  post-
ronchodilator  FEV1/FVC  <  0.70  with  occasional  dyspnea  and
 LABA  or  LAMA  when  dyspnea  is  persistent,21 and  another
xpert  proposed  the  division  of  GOLD  A  patients  into  two
ub-groups:  patients  with  FEV1 >  80%  and  with  no  worsening
f  FEV1 in  the  annual  assessment  should  be  treated  with  a
ABA  or  SAMA  only  in  SOS,  and  patients  with  50%  <  FEV1 <  80%
nd/or  worsening  of  FEV1 in  the  annual  assessment  should
e  treated  with  a  LABA  or  LAMA.3 However,  according  to
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BFigure  1  Proposed  diagnostic  and  treatment  alg
he  GOLD  2017  report,4 FEV1 should  no  longer  guide  treat-
ent,  but  symptoms  and  exacerbation  risk  instead,  and  as
uch,  recommendations  for  these  patients  are  either  a  short-
r  a  long-acting  bronchodilator,  which  can  be  switched  to
nother  class  of  bronchodilator  if  there  is  no  symptom
elief,  and  continued  or  discontinued  depending  on  symp-
omatic  benefit.  Therefore,  given  that  the  current  goals  of
aintenance  therapy  are  to  reduce  symptoms  and  prevent
xacerbations,  then  a  LABA  should  be  chosen  for  the  former
symptoms  reduction),22 and  a  LAMA  for  the  latter  (exacer-
ations  prevention)  since  it  has  been  reported  to  be  superior
o  LABA  regarding  exacerbation  prevention.23,24 Dual  bron-
hodilation  with  LABA/LAMA  should  not  be  offered  to  these
atients  because  they  are  neither  frequent  exacerbators  nor
ery  symptomatic.
It  is  worth  noting  that,  depending  on  the  instrument  used
or  the  classification  of  symptoms,  the  modified  Medical
esearch  Council  scale  (mMRC)  or  the  COPD  assessment  test
CAT),  a  patient  may  be  classified  as  A  or  B 25,26 and  therefore
oth  instruments  are  recommended.We  propose  that  chronic  maintenance  therapy  with  a
ABA  or  a  LAMA  should  be  offered  to  GOLD  A  patients.  We
gree  with  GOLD  2018  in  that  a  switch  to  another  class  of
ronchodilator  can  be  made  if  there  is  no  symptom  relief,
d
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tm  to  evaluate  and  medicate  pre-GOLD  patients.
nd  therapy  should  be  continued  or  discontinued  depending
n  symptomatic  benefit.
OLD  B  patients
lthough  inhaled  corticosteroids  (ICS)  are  not  recommended
s  maintenance  therapy  for  GOLD  B  patients,3,5,21,27 real-
orld  studies  or  baseline  characteristics  of  patients  enrolled
n  RCTs  show  that  up  to  51.8%  of  these  patients  are  still
edicated  with  ICS.28--33 In  a  paper  from  2016,  we  specu-
ated  that  this  was  mainly  due  to  the  generalized  idea  that
 patient  taking  ICS  will  be  more  controlled  than  a  patient
ho  is  not  on  ICS  therapy,  and  will  not  exacerbate  or  deterio-
ate,  which  is  not  true.3 Our  speculation  is  now  supported  by
vidence  from  the  FLAME  study,  that  randomized  a  total  of
680  patients  to  the  indacaterol/glycopyrronium  110/50  g
nce-daily  group  and  1682  to  the  salmeterol/fluticasone
0/500  g  twice-daily  group,  and  showed  that  for  GOLD
 patients  with  a  history  of  at  least  one  exacerbation
uring  the  previous  year,  indacaterol/glycopyrronium  was
ore  effective  than  salmeterol/fluticasone  in  preventing
OPD  exacerbations,  irrespective  of  prior  ICS/LABA/LAMA
herapy,7 and  was  associated  with  no  detectable  increase
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Table  1  proposed  division  of  GOLD  B  patients  in  two  subgroups  and  respective  therapeutic  approaches.
Sub-group  characteristics  Therapeutic  approach
BX1:  mMRC  =  2  AND  0  exacerbations;
AND  no  cardiovascular  co-morbidities
(a)  if  not  medicated,  initiate  LABA  or  LAMA
BX2: mMRC  >  2  OR
1 exacerbation  without  hospitalization  OR
with cardiovascular  co-morbidities
LABA  +  LAMA  (‘‘hit  hard’’  approach)
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imMRC -- modified Medical Research Council dyspnea scale; LABA -
in  adverse  events.6 The  FLAME  study  also  supports  our
previous  recommendation  that  B  patients  without  exacer-
bations,  who  are  overtreated  with  ICS,  should  be  withdrawn
from  ICS,3 and  further  suggests  that  even  B  patients  with
at  least  one  exacerbation  during  the  previous  year  can
and  should  be  withdrawn  from  ICS.6,7 Symptomatic  patients
are  more  likely  to  experience  exacerbations34 (the  ECLIPSE
study  showed  that  52%  of  these  patients  are  exacerbators),35
and  therefore  it  is  of  the  utmost  importance  to  control
symptoms,  namely  with  dual  bronchodilation,3,21,27 which
is  now  clearly  supported  by  the  FLAME  study  and  other
studies  from  the  IGNITE  clinical  development  program
for  indacaterol/glycopyrronium.6,7,36,37 In  the  Salford  Lung
Study,  a  large  randomized  open-label  trial  designed  to
mimic  real-world  conditions,  a  once-daily  treatment  regi-
men  of  combined  fluticasone  furoate/vilanterol  100/25  g
was  compared  to  usual  care,  and  the  authors  concluded  that
the  fluticasone  furoate/vilanterol  combination  was  associ-
ated  with  a  lower  rate  of  exacerbations  than  usual  care,
without  a  greater  risk  of  serious  adverse  events.38 It  is
our  opinion  that  this  study  does  not  contradict  the  FLAME
study  for  several  reasons:  in  the  Salford  Lung  Study38 22%  of
the  patients  included  had  a  diagnosis  of  asthma,  the  com-
parator  arm  was  usual  care  as  determined  by  the  general
practitioner,  which  resulted  in  a  variety  of  monotherapies
and/or  combination  therapies  (88%  of  patients  in  the  usual
care  group  were  receiving  an  ICS-containing  regimen),  and
unilateral  crossover  was  permitted.  Therefore,  the  conclu-
sions  drawn  by  the  authors  have  several  possible  sources
of  bias  and  it  is  not  possible  to  conclude  from  these  data
whether  fluticasone  and  vilanterol  is  more  effective  than  a
LABA/LAMA  at  reducing  exacerbations.
The  ECLIPSE35 and  FLAME6,7 studies  grouped  patients
according  to  the  GOLD  2016  report5 thus  including  FEV1 as  a
risk  criterion.  From  GOLD  2017  onwards1,4 FEV1 is  no  longer
a  criterion  for  risk,  only  symptoms  and  exacerbations.  The
FLAME  study  states  that  19.3%  of  patients  had  ≥2  exacerba-
tions,  and  these  will  now  be  the  GOLD  D  patients;  as  for  the
remaining  patients  involved  in  the  study,  those  with  ≤1  exac-
erbation  without  hospitalization,  will  be  now  classified  as
GOLD  B.  In  fact,  since  the  GOLD  2017  classification,1,4 it  is  to
be  expected  that  many  patients  formerly  classified  as  GOLD
D  would  now  be  classified  as  GOLD  B,  because  they  were
classified  as  GOLD  D  due  to  FEV1.  These  GOLD  B  patients  are
the  most  heterogeneous  and  unstable,  and  may  eventually
exacerbate.35 Thus,  the  conclusions  of  the  FLAME  study  hold
true  regardless  of  the  GOLD  stratification.
However,  with  this  new  classification,  and  as  many  for-
mer  GOLD  D  patients  will  now  be  considered  GOLD  B,  they
are  probably  on  ICS  therapy,  as  recommended  for  GOLD  D
w
w
t
m acting 2-agonist; LAMA -- long-acting muscarinic antagonist.
atients.  These  patients,  previously  classified  as  GOLD  D  due
o  FEV1 and  not  due  to  exacerbations,  should  be  withdrawn
rom  ICS.
In  a previous  paper  we  proposed  that  GOLD  B  patients
hould  be  divided  in  two  subgroups,  BX1  and  BX2,  and  the
herapeutic  approach  should  be  based  on  this  subdivision.3
ince  GOLD  2017  led  to  changes  in  COPD  patient  classifica-
ion,  in  this  paper  we  have  adapted,  our  proposal  as  shown
n  Table  1.
We  propose  that  ICS  should  not  be  given  to  GOLD  B
atients  as  maintenance  therapy.  We  further  propose  that
reviously  GOLD  D  patients  now  considered  GOLD  B  post
OLD  2017  and  who  are  on  ICS  therapy  should  be  withdrawn
rom  it,  and  be  monitored  3--6  months  later.3
OLD  C  patients
ccording  to  the  2017/2018  GOLD  C  new  classification,1,4 the
roups  C1  (high  risk  due  to  poor  lung  function)  and  C3  (high
isk  due  to  both  poor  function  and  exacerbations)3 no  longer
xist  and  all  GOLD  C  patients  will  be  classified  as  high  risk
ased  only  on  exacerbations.  Therefore,  the  main  therapeu-
ic  goal  will  be  to  reduce  the  risk  of  exacerbations.  As  initial
herapy  should  consist  of  a  single  long  acting  bronchodila-
or,  a  LAMA  should  be  preferred  to  a  LABA  since  it  has  been
eported  to  be  better  at  preventing  exacerbations.23,24
We  agree  with  GOLD  2018  that  these  patients  should  start
herapy  with  just  LAMA  and  then,  if  exacerbations  continue,
hould  preferably  be  switched  to  LABA/LAMA,  instead  of
ABA/ICS,  although  the  latter  remains  an  option.
OLD  D  patients
ow  to  start  therapy
any  guidelines  have  recommended  LABA/ICS  and/or  LAMA
s  first-line  therapy  for  higher  risk  patients.3,5 However,
ome  discrepancies  exist,  and  the  therapy  approach  to  these
atients  is  not  straightforward.3,21,27,33 A  meta-analysis  from
015  concluded  that  LAMA/LABA  seemed  to  be  a  better
ption  for  treating  GOLD  D  patients  (as  defined  pre-GOLD
017/2018)  than  LABA/ICS.39 The  FLAME  study  supports
his  conclusion,  favoring  indacaterol/glycopyrronium  ver-
us  salmeterol/fluticasone  in  preventing  exacerbations  in
OLD  D  patients  (as  defined  pre-GOLD  2017/2018),6 includ-
ng  patients  with  prior  triple  therapy.7 When  compared
ith  salmeterol/fluticasone,  indacaterol/glycopyrronium
as  better  at  preventing  all  exacerbations  and  delaying
he  time  to  first  exacerbation,  any  exacerbation  (p  <  0.001),
oderate-to-severe  exacerbations  (p  <  0.001)  and  severe
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xacerbations  (p  =  0.046).  The  improvement  over  time  in
he  total  score  on  the  St.  George’s  Respiratory  Question-
aire  for  COPD  patients  (SGRQ-C)  was  significantly  greater
han  salmeterol/fluticasone  after  day  85.  Also,  at  week
2,  the  percentage  of  patients  who  had  a  clinically  impor-
ant  decrease  of  at  least  4  points  in  the  total  score  on
he  SGRQ-C  was  significantly  higher  and  the  use  of  rescue
edication  was  significantly  improved  for  the  patients  in
he  indacaterol/glycopyrronium  treatment  arm  versus  those
n  the  salmeterol/fluticasone  arm.  On  subgroup  analysis,
he  advantage  of  indacaterol/glycopyrronium  was  partic-
larly  relevant  for  current  smokers,  patients  with  severe
irflow  limitation,  GOLD  D  patients,  patients  with  1  exac-
rbation  in  the  previous  year,  and  previous  use  of  LABA  or
AMA.  As  for  adverse  events,  indacaterol/glycopyrronium
as  not  associated  with  a  detectable  increase  in  adverse
vents  and  the  incidence  of  pneumonia  was  significantly
ower  in  the  indacaterol/glycopyrronium  group  than  in  the
almeterol/fluticasone  group  (3.2%  vs  4.8%,  p  =  0.02).  This
as  also  the  first  study  to  prospectively  analyze  the  rele-
ance  of  blood  eosinophilia  in  COPD,  and  the  results  were
imilar  for  blood  eosinophilia  <  2%  compared  to  ≥2%.  Other
nalyses  in  subgroups  defined  according  to  different  cut-
ffs  of  baseline  blood  eosinophil  counts  provided  similar
esults.6,8
Data  from  the  first  head-to-head  study  (TRIBUTE)
omparing  a  triple  combination  of  LABA/LAMA/ICS
beclometasone/formoterol/glycopyrronium,
00/6/12.5  g,  two  inhalations  twice-daily)  with  a  dual
ombination  of  LABA/LAMA  (IND/GLY)  have  just  recently
een  published.40 The  TRIBUTE  study  enrolled  symptomatic
atients  (CAT  ≥  10)  with  a  FEV1 <  50%  and  a  history  of  at
east  one  documented  moderate  or  severe  exacerbation  in
he  past  year.  The  primary  endpoint  analysis  showed  a  15%
eduction  in  the  rate  of  moderate  to  severe  exacerbations
avoring  the  triple  combination  when  compared  with  the
ual  combination  (p  =  0.043).  It  should  be  noted  that  no
ignificant  difference  between  treatment  regimens  was
bserved  when  moderate  and  severe  exacerbations  were
nalyzed  separately  (p  =  0.118  and  p  =  0.189,  respectively)
r  for  the  time  to  first  moderate  or  severe  exacerbation
p  = 0.219)  and  time  to  first  severe  exacerbation  (p  =  0.405).
n  addition,  the  pre-specified  subgroup  analyses  suggest
hat  patients  with:  FEV1 <  30%,  or  emphysema  or  a  mixed
henotype,  or  >1  exacerbation  in  the  previous  12  months,
r  lower  blood  eosinophils  (<2%  or  <200  cells/L) may  not
erive  any  benefit  from  LABA/LAMA/ICS  compared  with
ABA/LAMA.  Interestingly,  the  incidence  of  pneumonia
as  similar  between  the  two  regimens.  The  results  from
RIBUTE  are  entirely  in  line  with  the  current  GOLD  rec-
mmendations  and  indicate  that  patients  with  chronic
ronchitis  and  elevated  blood  eosinophil  counts  will  be
ore  likely  to  benefit  from  a  triple  combination  regimen.
ecent  data  from  the  IMPACT  study  also  appear  to  be  in
ine  with  the  GOLD  recommendations  with  triple  therapy
ith  fluticasone  furoate/umeclidinium/vilanterol  showing
enefits  in  patients  with  frequent  exacerbations  and  in
hose  with  a  severe  exacerbation  in  the  12  months  previous
o  study  enrollment  when  compared  with  fluticasone
uroate/vilanterol  and  umeclidinium/vilanterol.41 Despite
his,  and  as  mentioned  by  Suissa  &  Drazen,  in  an  Editorial  on
he  IMPACT  study42:  ‘‘However,  the  selected  trial  patients,
F
F
rN.  Pires  et  al.
ost  of  whom  were  already  treated  with  inhaled  glucocor-
icoids  and  some  of  whom  had  a  history  of  asthma,  were
ot  the  natural  population  in  which  to  study  this  question,
otentially  artificially  inflating  the  observed  effectiveness
f  the  triple-therapy  inhaler  over  dual  bronchodilator
reatment’’.  Consequently,  the  patient  population  involved
n  the  IMPACT  study  makes  it  very  difficult  to  interpret  these
ata  and  come  to  a  clear  conclusion  about  its  relevance  for
he  management  of  COPD  patients.
In  face  of  the  results  described  above,  we  recommend
hat  GOLD  D  patients  should  start  therapy  with  dual  bron-
hodilation,  and  ICS  should  only  be  used  as  an  add-on  if
atients  have  further  exacerbations.  We  also  propose  that
CS  should  not  be  given  to  these  patients  as  first  line  main-
enance  therapy.
f  and  when  to  add  ICS
 recent  post  hoc  analysis  of  the  WISDOM  study  concluded
hat  a  history  of  ≥2  exacerbations  per  year  plus  an  eosinophil
ount  ≥300  cells/L identifies  individuals  at  increased  risk
f  exacerbation  when  ICS  is  discontinued.  These  authors
eport  that  the  most  consistent  and  greatest  effect  was
een  in  patients  with  ≥2  exacerbations  and  ≥400  cells/L.
evertheless,  the  authors  recognize  that,  given  the  rela-
ively  small  sample  sizes,  more  studies  are  needed,  along
ith  prospective  confirmation  of  the  validity  of  the  pro-
osed  subgroups  of  ICS-responsive  individuals.43 New  data  on
his  subject  have  now  been  provided  by  the  SUNSET  study
here  non-frequently  exacerbating  patients  on  long-term
riple  therapy  with  tiotropium  plus  salmeterol/fluticasone
ere  randomized  to  either  continue  their  triple  therapy  reg-
men  or  switch  to  indacaterol/glicopirronium.44 The  switch
o  indacaterol/glycopirronium  led  to  a  small  reduction  in
ung  function  (-26  mL  in  trough  FEV1)  but  no  difference  in
OPD  exacerbations  between  treatment  groups.  In  addition,
he  study  also  demonstrates  that  patients  with  higher  blood
osinophil  counts  of  ≥300  cells/L are  more  likely  to  ben-
fit  from  triple  therapy  as  far  as  loss  of  lung  function  is
oncerned.44
Due  to  the  lack  of  more  conclusive  data,  the  rec-
mmended  treatment  approach  is  the  one  proposed
reviously.3,21,27
onclusions
ased  on  the  GOLD  2017/2018  and  on  new  evidence  that  has
merged  regarding  treatment  options  with  the  FLAME  study,
his  paper  provides  an  update  on  a  previous  proposal  for
harmacological  treatment  approaches  to  COPD  patients.
lso,  the  concept  of  Pre-GOLD  patients,  which  has  diagnos-
ic,  prognostic  and  therapeutic  implications,  is  introduced,
long  with  a  proposed  algorithm  for  the  identification  and
reatment  of  these  patients.
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